| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
| Recent legal settlements and FDA approvals have led to significant developments in vaccine and obesity drug sectors, reflecting active engagement and innovation. Positive earnings reports and advancements in AI technology indicate a growing market opportunity, particularly for aging populations. However, uncertainty around drug pricing and job losses due to strikes pose ongoing challenges for the industry. The interplay of demographic shifts and healthcare spending will continue to influence market dynamics in the near future. The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The trend sentiment at -0.9 is bearish. The market sentiment at 0.4 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for XLV since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for Health Care sector is at 0.6, and the negative at -0.2 on 2026-03-10. The forces of Sentiment towards Fundamentals (1.9), Market Risk Appetite (1), Price Level Sentiment (0.5), Option Sentiment (0.3), and Valuation Sentiment (0.1) will drive up the price. The forces of Broad Market Trend (-0.4), and Sector Price Trend (-0.9) will drive down the price. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice Sector Rotation Notification
| XLV | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | 3%(1.7%) | 153.21 | 1.21% | 4 | -0.7% | -0.32% | -0.9 | 0 | 0.5% | 0.4 | Wait | 50% | 1.9 | 1.2 |
| 2026-03-09 | 2%(1.4%) | 154.29 | 1.08% | 12 | 0.98% | -0.25% | -0.9 | 0.3 | 0.5% | 0.5 | Wait | 50% | 1.7 | 5.6 |
| 2026-03-08 | 1%(1.4%) | -1.4 | -0.2 | 1.7 | 2.8 | |||||||||
| 2026-03-07 | 2%(1.3%) | -1.4 | -0.1 | 1.8 | 1.8 | |||||||||
| 2026-03-06 | 1%(1%) | 152.8 | 1.03% | -16 | -0.74% | -0.25% | -1.4 | 0 | 1.4% | 0.2 | Wait | 50% | 1.8 | -0.9 |
| 2026-03-05 | 1%(1%) | 153.94 | 0.88% | -8 | -1.98% | -0.19% | -0.7 | -0.4 | 1.1% | 0.9 | Wait | 50% | 2.1 | 6.1 |
| 2026-03-04 | 2%(1%) | 157.05 | 0.75% | 47 | 0.17% | -0.06% | -0.1 | -0.1 | 0.6% | 0.7 | Short | 55% | 2.1 | 5.2 |
| 2026-03-03 | 1%(0.9%) | 156.78 | 0.87% | 46 | -1.11% | -0.06% | -0.3 | -0.1 | 0.9% | 0.5 | Short | 55% | 2 | 2.3 |
| 2026-03-02 | 2%(1%) | 158.54 | 0.88% | 78 | -1.02% | 0.06% | 0.2 | 0 | 0.6% | 0.8 | Long | 55% | 2.1 | 3.1 |
| 2026-03-01 | 0%(1.1%) | 0.9 | 0.6 | 2.3 | -0.5 | |||||||||
| Wait is the preferred trading strategy with 50% chance of being right. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Health Care Sector Check-Up: What Analysts Are Saying Right Now Mon. Sep 29, 2025 | ||
| Market News | ||
| 1 (5) Hims Hires Ex-Lilly PR Chief as Its Weight-Loss Strategy Shifts Hims & Hers Health Inc. has hired Kathryn Beiser, who led communications at Eli Lilly & Co. for five years, as the telehealth company charts a new era selling brand-name obesity drugs. (https://www.bloomberg.com/) Tue. Mar 10, 2026 | ||
| 2 (8) Novo Nordisk and Hims & Hers are friends again Hims will start selling oral and injectable versions of Novo’s blockbuster obesity and diabetes medications later this month. (https://www.morningbrew.com/) Tue. Mar 10, 2026 | ||
| 3 (8) Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives. (https://www.marketbeat.com/) Tue. Mar 10, 2026 | ||
| 4 (7) Medtronic To Buy Scientia Vascular Medtronic PLC (MDT, 2M6.DE), an Irish healthcare technology company, said on Tuesday that it has inked a deal to acquire Scientia Vascular. The acquisition is valued at $550 million, with potential undisclosed earn-out and milestone payments post-acquisition. (https://www.rttnews.com/) Tue. Mar 10, 2026 | ||
| 5 (8) Veeva Systems To Acquire Ostro For About $100 Mln Veeva Systems announced it has acquired Ostro for approximately $100 million in cash and long-term equity retention grants. Ostro provides an AI-driven brand engagement platform that enables patients and healthcare professionals to receive compliant answers and information through conversational chat interfaces on pharmaceutical brand websites. (https://www.rttnews.com/) Tue. Mar 10, 2026 | ||
| 6 (8) Vertex Just Reported Trial Results for a Kidney Drug. What It Means for the Stock. Vertex stock rallies after the drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial. (https://www.barrons.com/) Tue. Mar 10, 2026 | ||
| 7 (-6) Obamacare enrollment is plunging as costs soar, pushing down stocks like Centene Americans are opting out of the Affordable Care Act, and health insurance companies are taking a financial hit. (https://www.marketwatch.com/) Tue. Mar 10, 2026 | ||
| 8 (-6) Centene Is the Worst S&P 500 Stock Today. What’s Ailing the Health Insurer. Centene’s CEO says the company expects to see a continued contraction in its Affordable Care Act marketplace. (https://www.barrons.com/) Tue. Mar 10, 2026 | ||
| 9 (-6) Centene Is the Worst S&P 500 Stock Today. What’s Ailing the Health Insurer. Centene’s CEO says the company expects to see a continued contraction in its Affordable Care Act marketplace. (https://www.barrons.com/) Tue. Mar 10, 2026 | ||
| 10 (-7) Obamacare enrollment is plunging as costs soar, pushing down stocks like Centene Americans are opting out of the Affordable Care Act, and health insurance companies are taking a financial hit. (https://www.marketwatch.com/) Tue. Mar 10, 2026 | ||
| 11 (3) Wall Street Gets Less Bearish on Hims & Hers After Novo Nordisk Truce. Stock Gains Could Still Be Limited. Hims & Hers received a flurry of upgrades, though most analysts are opting to stay on the sidelines. Here’s why. (https://www.barrons.com/) Tue. Mar 10, 2026 | ||
| 12 (0) Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more These are some of the stocks seeing the largest midday moves. (https://www.cnbc.com/) Tue. Mar 10, 2026 | ||
| 13 (7) 8 Stocks to Buy as Merger-Mania Takes Over Consolidation wave creates opportunities for patient investors. 8 sectors leading now are health, semiconductors, medical devices, and media. (https://www.benzinga.com/) Tue. Mar 10, 2026 | ||
| 14 (-7) Centene shares fall as health insurer sees steeper drop in Obamacare memberships By Sriparna Roy March 10 (Reuters) - Centene shares fell as much as 13% on Tuesday after company executives flagged the health insurer is seeing lower number of members in some Affordable Care Act plans, also known as Obamacare. The ACA marketplace uses metal levels to categorize plans. (https://finance.yahoo.com/) Tue. Mar 10, 2026 | ||
| 15 (-7) FDA Warns Novo Over Unreported Potential Ozempic Side Effects, Deaths Novo Nordisk A/S got a warning letter from the US Food and Drug Administration for not reporting all suspected side effects in patients who took its blockbuster Ozempic. (https://www.bloomberg.com/) Tue. Mar 10, 2026 | ||
| 16 (6) Teladoc Health Stock Pops - Here's Why Teladoc Health stock jumps after beating earnings estimates, even as cautious 2026 guidance and mixed analyst views emerge. (https://www.benzinga.com/) Tue. Mar 10, 2026 | ||
| 17 (6) S&P 500 Futures Steady in Premarket Trading; Vertex Pharmaceuticals, UFP Industries Lead With U.S. stock markets set to open in two hours, Vertex Pharmaceuticals Inc. (VRTX) was up 6.2% in pre-market trading, and UFP Industries Inc. (UFPI) was up 5.0%. (https://www.barrons.com/) Tue. Mar 10, 2026 | ||
| 18 (8) Vertex Stock Jumps. What Wall Street Is Saying About Its Kidney Drug Trial. Vertex stock rallies after the drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial. (https://www.barrons.com/) Tue. Mar 10, 2026 | ||
| 19 (6) How a Die-Hard Libertarian Is Negotiating Lower Health-Care Costs An anesthesiologist has spent decades pushing his surgery center toward more transparent prices. Others are now following his lead. (https://www.bloomberg.com/) Tue. Mar 10, 2026 | ||
| 20 (-3) TD Cowen downgrades Novo Nordisk on concerns over semaglutide patent loss, pipeline outlook TD Cowen still sees shares of Novo Nordisk adding 6% from here. (https://www.cnbc.com/) Tue. Mar 10, 2026 | ||
| 21 (0) Stocks making the biggest moves premarket: Kohl's, Casey's General Stores, Vertex Pharmaceuticals and more These are the stocks posting the largest moves in early trading. (https://www.cnbc.com/) Tue. Mar 10, 2026 | ||
| 22 (8) Medtronic to buy Scientia Vascular in $550 million deal March 10 () - Medical device maker Medtronic said on Tuesday it has agreed to buy U.-based Scientia Vascular in a deal valued at $550 million, aiming to expand its line-up of products used in stroke care. (https://finance.yahoo.com/) Tue. Mar 10, 2026 | ||
| 23 (-6) Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen. Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat. (https://www.marketwatch.com/) Tue. Mar 10, 2026 | ||
| 24 (8) Uber expands Women Preferences, Hims & Hers stock skyrockets Yahoo Finance Senior Reporter Brooke DiPalma and Market Domination host Josh Lipton discuss some of Monday's top trending stories. Ticketmaster parent company Live Nation (LYV) reached a settlement in a monopolization lawsuit with the US Department of Justice (DOJ). Hims & Hers (HIMS) stock skyrocketed on Monday after a big win: the company struck a deal with Novo Nordisk (NVO) to bring GLP-1 drugs Ozempic and Wegovy onto its platform. Uber's (UBER) "Women Preferences" feature is expanding nationwide. To watch more expert insights and analysis on the latest market action, check out more Market Domination. (https://finance.yahoo.com/) Mon. Mar 9, 2026 | ||
| 25 (8) Hims & Hers stock skyrockets 40% as Novo Nordisk ends feud, agrees to sell Ozempic and Wegovy on platform Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant. (https://www.marketwatch.com/) Mon. Mar 9, 2026 | ||
| 26 (8) Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? Hims & Hers stock traded more than 40% higher after the deal was announced. (https://www.fool.com/) Mon. Mar 9, 2026 | ||
| 27 (5) Hims partners with Novo Nordisk, Live Nation settles antitrust suit Market Catalysts host Julie Hyman takes a look at some of Monday morning's trending tickers and stories, including Hims & Hers Health (HIMS) to start selling Novo Nordisk's (NVO) GLP-1 weight-loss drugs on its platform, Live Nation (LYV) settling its antitrust lawsuit with the Department of Justice (DOJ), and cruise line stocks taking a hit from escalations in the Iran war. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Mon. Mar 9, 2026 | ||
| 28 (8) Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform Hims stock surged more than 40% Monday morning on news that Novo Nordisk will distribute its weight-loss drugs through the Hims platform. (https://finance.yahoo.com/) Mon. Mar 9, 2026 | ||
| 29 (2) Hims & Hers Erupts In Epic Squeeze As Novo Nordisk Ends GLP-1 Feud ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero (https://www.zerohedge.com/) Mon. Mar 9, 2026 | ||
| 30 (0) Hims & Hers Health Inc. Complete Hims & Hers Health Inc. stock information by Barron's. View real-time HIMS stock price and news, along with industry-best analysis. (https://www.barrons.com/) Mon. Mar 9, 2026 | ||
| 31 (8) Hims & Hers Stock Soars 53%. It’s Struck a Truce With Novo Nordisk, Report Says. Novo Nordisk has agreed to sell its weight-loss injectables and its Wegovy pill on Hims’ platform. (https://www.barrons.com/) Mon. Mar 9, 2026 | ||
| 32 (8) Hims & Hers Stock Soars 53%. It’s Struck a Truce With Novo Nordisk, Report Says. Novo has agreed to sell its weight-loss drugs on Hims’ platform, according to a report. (https://www.barrons.com/) Mon. Mar 9, 2026 | ||
| 33 (6) Novo Drops Hims & Hers Lawsuit and Will Sell Wegovy on Site Novo Nordisk A/S and Hims & Hers Health Inc. will work together to sell obesity drugs, a sudden reversal after more than eight months of acrimony that culminated in a legal battle. (https://www.bloomberg.com/) Mon. Mar 9, 2026 | ||
| 34 (8) Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines. (https://www.cnbc.com/) Mon. Mar 9, 2026 | ||
| 35 (9) Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars Hims & Hers stock jumps 49% premarket after ending lawsuit with Novo Nordisk and securing weight-loss drug partnership. (https://www.benzinga.com/) Mon. Mar 9, 2026 | ||
| 36 (-5) Roche's Breast Cancer Drug Falls Short In Phase 3 Study Roche's phase 3 persevERA breast cancer trial misses its primary goal, though numerical gains were seen. See the full clinical breakdown. (https://www.benzinga.com/) Mon. Mar 9, 2026 | ||
| 37 (7) Universal Health strikes $835 million Talkspace deal in mental health push March 9 () - Hospital operator Universal Health Services said on Monday it would acquire virtual healthcare provider Talkspace in a deal valued at $835 million, amid rising demand for behavioral health services. Universal Health Services will pay $5. (https://finance.yahoo.com/) Mon. Mar 9, 2026 | ||
| 38 (7) Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit COPENHAGEN, March 9 (Reuters) - Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the Danish drugmaker said on Monday, (https://finance.yahoo.com/) Mon. Mar 9, 2026 | ||
| 39 (8) Hims & Hers stock rockets on end to Novo Nordisk weight-loss drug dispute Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant. (https://www.marketwatch.com/) Mon. Mar 9, 2026 | ||
| 40 (8) Hims & Hers stock rockets on end to Novo Nordisk weight-loss drug dispute Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant. (https://www.marketwatch.com/) Mon. Mar 9, 2026 | ||
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA